Expression vector of human ACH.
Alternative name | SET-0026_126 |
---|---|
Clone info. | Expression vector of human ADR. Expression was confirmed by Western blotting with anti-FLAG antibody. |
Comment | Derived from Sugano BC011564. PCR cloning, forward primer: gcgggcgagaaccaccagtg; reverse primer: ttatatctttgtacagagcatttcca. |
Vector backbone | pCMV_S-FLAG (RDB05956) (Plasmid) |
Size of vector backbone | 5.5 kb |
Selectable markers | Amp^r (E. coli), Neo^r (mammalian cell) |
Growth conditions | 37C, LB+Amp |
Gene/insert name | Human DAX1;ACH cDNA |
Depositor|Developer | DNA Bank, | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms | Order form [Credit Card Payment ![]() ![]() ![]() MTA, for use for not-for-profit academic purpose [Word ![]() ![]() MTA, for use for for-profit purpose [Word ![]() Please visit Information of Request for Distribution.[link] |
---|---|
Terms and conditions for distribution | The RECIPIENT agrees to describe RIKEN BRC as the source of the MATERIAL and cite Gene 200, 149-156, 1997 in any publication. Additional terms and conditions: Regrding pRc/CMV: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
必要書類 | 提供依頼書 ![]() ![]() 提供同意書 (MTA, 非営利学術目的用)[Word ![]() ![]() 提供同意書 (MTA, 営利目的用)[Word ![]() 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
---|---|
MTAに書く使用条件 | 発表に際し、理研BRCから入手したことを明記し、指定する文献(Gene, 200, 149-156 (1997))を引用すること。 付加的使用条件: pRc/CMVについて: a) The modified pRc/CMV, and their descendants (collectively, LIFE MATERIALS), should be used for pre-clinical/non-human, research use only. b) LIFE MATERIALS shall not be used for any commercial purposes. c) LIFE MATERIALS shall not be transferred beyond the specified recipient. d) Recipient must contact Thermo Fisher Scientific Inc. at outlicense@thermofisher.com for any desired use of LIFE MATERIALS beyond the scope of a) to c) above. |
Catalog # | Resource name | Shipping form | Fee |
---|---|---|---|
RDB06297 | pCMFlag_hsNR0B1 | DNA solution |
JPY 9,460 (not-for-profit academic purpose) JPY 18,920 (for-profit-research purpose) plus cost of shipping containers, dry ice (if required) and shipping charge |
Materials & Methods section:
The pCMFlag_hsNR0B1 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB06297). |
Reference section:
Further references such as user reports and related articles (go to bottom)
RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by icon as well as clone information before placing your order.
Test sheet | RDB06297_A3Irp2.pdf ![]() |
---|
Nucleotide sequence of a portion of this resource (if available).
Primer: CMV-Forward Sequence file: RDB06297_A3Ira.seq ![]() |
---|
>06297_06297_A3Ir_CMV-Foward_E11_14.ab1 1 TGTATCAACT TCCGCCCATT GACGCAAATG GGCGGTAGGC GTGTACGGTG GGAGGTCTAT 61 ATAAGCAGAG CTCTCTGGCT AACTAGAGAA CCCACTGCTT ACTGGCTTAT CGAAATTAAT 121 ACGACTCACT ATAGGGAGAC CCAAGCTGAA TTCACCATGG ACTACAAGGA CGATGACGAT 181 AAGGCGGCCG CGGGCGAGAA CCACCAGTGG CAGGGCAGCA TCCTCTACAA CATGCTTATG 241 AGCGCGAAGC AAACGCGCGC GGCTCCTGAG GCTCCAGAGA CGCGGCTGGT GGATCAGTGC 301 TGGGGCTGTT CGTGCGGCGA TGAGCCCGGG GTGGGCAGAG AGGGGCTGCT GGGCGGGCGG 361 AACGTGGCGC TCCTGTACCG CTGCTGCTTT TGCGGTAAAG ACCACCCACG GCAGGGCAGC 421 ATCCTCTACA GCATGCTGAC GAGCGCAAAG CAAACGTACG CGGCACCGAA GGCGCCCGAG 481 GCGACGCTGG GTCCGTGCTG GGGCTGTTCG TGCGGCTCTG ATCCCGGGGT GGGCAGAGCG 541 GGGCTTCCGG GTGGGCGGCC CGTGGCACTC CTGTACCGCT GCTGCTTTTG TGGTGAAGAC 601 CACCCGCGGC AGGGCAGCAT CCTCTACAGC TTGCTCACTA GCTCAAAGCA AACGCACGTG 661 GCTCCGGCAG CGCCCGAGGC ACGGCCAGGG GGCGCGTGGT GGGACCGCTC CTACTTCGCG 721 CAGAGGCCAG GGGGTAAAGA GGCGCTACCA GGCGGGCGGG CCACGGCGCT TCTGTACCGC 781 TGCTGCTTTT GCGGTGAAGA CCACCCGCAG CAGGGCAGCA CCCTCTACTG CGTGCCCACG 841 AGCACAAATC AAGCGCAGGC GGCTCCGGAG GAGCGGCCGA GGGCCCCCTG GTGGGACACC 901 TCCTCTGGTG CGCTGCGGCC GGTGGCGCTC AAGAGTCCAC AGGTGGTCTG CGAGGCAGCC 961 TCAGCGGGCC TGTTGAAGAC GCTGCGCTTC GTCAAGTACT TGCCCTGCTT CCAGGTGCTG 1021 CCCCTGGACC AGCAGCTGGG TGCTGGGTGC GCAACTGCTG GCGTCCCTGC TCATGCTGAG 1081 CTGGGCCCAG GACCGCTTGC AGATCGAGAC CTGTGAGTCT CGGAGCTCAG CATGCTGCCA 1141 GAAAAGAAAT TCCCTTCCAA CCGAC // |
Primer: SP6 Sequence file: RDB06297_A3Irb.seq ![]() |
>06297_06297_A3Ir_Sp6_F11_17.ab1 1 CCTTTAGTCA TGCCTCGAGC GGCCTTATAT CTTTGTACAG AGCATTTCCA GCATCATATC 61 ATCCATGCTG ACTGTGCCGA TGATGGGCCT GAAGAACAGT TCAGCAATGA CATTGGCATT 121 GATGAATCTC AGCAGGAAAA GGGTACTATT AAGTTCGATG AATCTGTCAT GGGGCCCTTG 181 GTGCGTCATC CTGGTGTGTT CACTGAGTAT TTGCTGAGTT CCCCACTGGA GTCCCTGAAT 241 GTACTTCACG CACTGCAGGC CCGGCACGTC CGGGTTAAAG AGCACGGTCC CCTTGAGGTA 301 GGCGTACTCC TTGGTACTGA TGTTCAGACT CCAGCATTTG GAAAGAAAGC ACTTGATGGC 361 TTGGACCTGG GAGGCGGAGG GCACCTTCCT GGCCTCCGCC GGCGGTGCCA AATGGTGCTG 421 CAGCGTGGGC ACGGGCAGTG GCTCGTTGCC CCCGGTCTCC CGCCGCCTGG TGGTGAGGAT 481 CTTCTGCAGC ATGCTGGGCT CCGAGACTTC CACAGTCTCG AACTGCAAGC GGTCCTGGGC 541 CAGCTCAAGC ATGAGCAGGG ACGCCCAGCA GTTGCGCACC AGCACCAGCT GCTGGTCCAG 601 GGGCAGCACC TGGAAGCAGG GCAAGTACTT GACGAAGCGC AGCGTCTTCA ACAGGCCCGC 661 TGAGGCTGCC TCGCAGACCA CCTGTGGACT CTTGAGCGCC ACCGGCCGCA GCGCACCAGA 721 GGAGGTGTCC CACCAGGGGG CCCTCGGCCG CTCCTCCGGA GCCGCCTGCG CTTGATTTGT 781 GCTCGTGGGC ACGCAGTAGA GGGTGCTGCC CTGCTGCGGG TGGTCTTCAC CGCAAAAGCA 841 GCAGCGGTAC AGAAGCGCCG TGGCCCGCCC GCCTGGTAGC GCCTCTTTAC CCCCTGGCCT 901 CTGCGCGAAG TAGGAGCGGT CCCACCACGC GCCCCCTGGC CGTGCCTCGG GCGCTGCCGG 961 AGCCACGTGC GTTTGCTTTG AGCTAGTGAG CAAGCTGTAG AGGATGCTGC CCTGCCGCGG 1021 GTGGGTCTTC ACCACAAAAG CAGCAGCGGG TACAGGGAGT GCCACGGGGC CCGCCCACCC 1081 CGGGAAGCCC CGCTCTGCCC CAACCCCGGG ATTCAGAGCG CACGAACCAG CTTCAGCACG 1141 GGAACCCAGG CCGAATCGTC ATG // |
Primer: SV40pro_F_V2 Sequence file: RDB06297_A3Irc.seq ![]() |
>06297_06297_A3Ir_SV40pro_F_V2_G02_07_ABI08.ab1 1 GGCACAACCT TTTTTTGGGG GGGGCTTAGG GCTTTTGCAA AAAGCTCCCG GGGAGCTTGG 61 ATATCCATTT TCGGATCTGA TCAAGAGACA GGATGAGGAT CGTTTCGCAT GATTGAACAA 121 GATGGATTGC ACGCAGGTTC TCCGGCCGCT TGGGTGGAGA GGCTATTCGG CTATGACTGG 181 GCACAACAGA CAATCGGCTG CTCTGATGCC GCCGTGTTCC GGCTGTCAGC GCAGGGGCGC 241 CCGGTTCTTT TTGTCAAGAC CGACCTGTCC GGTGCCCTGA ATGAACTGCA GGACGAGGCA 301 GCGCGGCTAT CGTGGCTGGC CACGACGGGC GTTCCTTGCG CAGCTGTGCT CGACGTTGTC 361 ACTGAAGCGG GAAGGGACTG GCTGCTATTG GGCGAAGTGC CGGGGCAGGA TCTCCTGTCA 421 TCTCACCTTG CTCCTGCCGA GAAAGTATCC ATCATGGCTG ATGCAATGCG GCGGCTGCAT 481 ACGCTTGATC CGGCTACCTG CCCATTCGAC CACCAAGCGA AACATCGCAT CGAGCGAGCA 541 CGTACTCGGA TGGAAGCCGG TCTTGTCGAT CAGGATGATC TGGACGAAGA GCATCAGGGG 601 CTCGCGCCAG CCGAACTGTT CGCCAGGCTC AAGGCGCGCA TGCCCGACGG CGAGGATCTC 661 GTCGTGACCC ATGGCGATGC CTGCTTGCCG AATATCATGG TGGAAAATGG CCGCTTTTCT 721 GGATTCATCG ACTGTGGCCG GCTGGGTGTG GCGGACCGCT ATCAGGACAT AGCGTTGGCT 781 ACCCGTGATA TTGCTGAAGA GCTTGGCGGG CGAAATGGGC CTGACCGCTT CCTCGTGCTT 841 TACGGTATCG CCGCTCCCGA TTCGCAGCGC ATCGCCTTTC TATCGCCTTT CTTGACGAGG 901 TTCTTCTGAG CGGGACTCTG GGGGTTCGAA ATGACCGACC AAGCGACGCC CCAACCTGGC 961 CCATCACGAG ATTTCGATCC ACCCGCCGCC CTTCTATGAA AAGGTTGGGG CTTCGGAAAT 1021 CGTTTTCCGG GACGCCCGGC CTGGGATGAT CCCTCCCAGC GCGGGGATCT CATGGCTGGG 1081 AGTTCTTCCG CCCAACCCCG AACTGCTTTA TTGCCAGCCT TATAAATGGG TTACAAGTAA 1141 AACATAGCCA TCCACCAAAG TTCACCAAAT CAAGCATTTT TTCACTTGCG ATTCCTAGTT 1201 TGGTGGTATT TGTCCCAAAA CTCTCCATCT ACGAACTTGT AGAATCAC // |
Please visit Sequencing and PCR primers for primer information.
Original, user report and related articles
Featured content